Treatment of an Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Harboring STAT3::JAK2 With Jakafi (Ruxolitinib) With Significant Clinical Improvements
ABSTRACT Introduction Indolent T‐cell lymphoma of the gastrointestinal tract (ITCL‐GI) is a rare primary T‐cell lymphoma from the gastrointestinal (GI) tract, there has been no documented successful treatment at the present time. Results A CD4(+)/CD8(−) ITCL‐GI with STAT3::JAK2 fusion was treated wi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | eJHaem |
| Online Access: | https://doi.org/10.1002/jha2.70047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|